Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2022-03-03

Clinical Trial Update: Mylan Insulin Glargine Study [Phase 3]

View source ↗

Summary

Phase 3 trial update for Mylan insulin glargine in Type 1 diabetes; study completed with results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Insulin Glargine (insulin glargine)

Snippet

Sponsor: Mylan Inc. | Conditions: Diabetes Mellitus, Type 1 | Phase 3 | Status: COMPLETED | Results posted: 2022-03-03